Literature DB >> 28084203

Tuberculous Otomastoiditis.

Jonathan M Hand1,2, George A Pankey1.   

Abstract

Tuberculous otitis media and mastoiditis, or tuberculous otomastoiditis, is a rare but well-described infectious process occasionally affecting individuals in the United States but more frequently seen in countries where tuberculosis is endemic. Infection may be primary and occur through mucus aspirated through the Eustachian tube. Alternatively, organisms may secondarily infect the nasopharynx when expectorated from the lungs and, less frequently, may be hematogenously spread. Chronic otorrhea and hearing loss are common symptoms, and extensive perforation of the tympanic membranes and facial nerve paralysis are routinely described. Diagnosis is made by direct culture of Mycobacterium tuberculosis, although more recently, molecular techniques have been used. Successful treatment of tuberculous otomastoiditis routinely involves surgical intervention combined with prolonged antituberculosis therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28084203     DOI: 10.1128/microbiolspec.TNMI7-0020-2016

Source DB:  PubMed          Journal:  Microbiol Spectr        ISSN: 2165-0497


  3 in total

1.  Primary bilateral tuberculous otitis media with peripheral facial paralysis: a case report and literature review.

Authors:  Ming Guan; Jie Zhang; Yuezhi Jia; Yaoshu Teng; Xiaolin Cao; Yong Li
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

2.  Facial canal dehiscence, dural exposure, and labyrinthine fistula in middle ear cholesteatoma and mastoiditis.

Authors:  Ning-Chia Chang; Shu-Yu Tai; Kuan-Hui Li; Hua-Ling Yang; Kuen-Yao Ho; Chen-Yu Chien
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-04       Impact factor: 3.236

3.  Aerobic bacteria associated with chronic suppurative otitis media in Angola.

Authors:  Fabian Uddén; Matuba Filipe; Åke Reimer; Maria Paul; Erika Matuschek; John Thegerström; Sven Hammerschmidt; Tuula Pelkonen; Kristian Riesbeck
Journal:  Infect Dis Poverty       Date:  2018-05-03       Impact factor: 4.520

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.